KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Receivables - Other: 2019-2023

Historic Receivables - Other for Royalty Pharma (RPRX) over the last 4 years, with Dec 2023 value amounting to $14.2 million.

  • Royalty Pharma's Receivables - Other fell 15.38% to $14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.2 million, marking a year-over-year decrease of 15.38%. This contributed to the annual value of $14.2 million for FY2023, which is 15.38% down from last year.
  • Royalty Pharma's Receivables - Other amounted to $14.2 million in Q4 2023, which was down 12.95% from $16.4 million recorded in Q3 2023.
  • Royalty Pharma's 5-year Receivables - Other high stood at $59.7 million for Q3 2021, and its period low was $14.2 million during Q4 2023.
  • Moreover, its 3-year median value for Receivables - Other was $17.4 million (2022), whereas its average is $28.8 million.
  • In the last 5 years, Royalty Pharma's Receivables - Other soared by 84.29% in 2021 and then slumped by 73.66% in 2022.
  • Over the past 5 years, Royalty Pharma's Receivables - Other (Quarterly) stood at $33.5 million in 2019, then fell by 1.10% to $33.2 million in 2020, then surged by 60.72% to $53.3 million in 2021, then slumped by 68.42% to $16.8 million in 2022, then decreased by 15.38% to $14.2 million in 2023.
  • Its Receivables - Other was $14.2 million in Q4 2023, compared to $16.4 million in Q3 2023 and $16.4 million in Q2 2023.